Acadia Pharmaceuticals reported negative results Monday from a pair of late-stage clinical trials seeking to expand the use of its antipsychotic medicine Nuplazid to patients with major depressive disorder.
The two identically designed Phase 3 clinical trials involved 300 patients who hadn’t responded well to currently approved depression treatments. In both studies, Nuplazid failed to demonstrate an anti-depressive benefit compared to a placebo when given to patients alongside their current medicines.
About the Author Reprints
